| Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways P Eroles, A Bosch, J Alejandro Pérez-Fidalgo, A Lluch Cancer Treatment Reviews, 2011 | 692 | 2011 |
| Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor–positive breast cancer R Jeselsohn, R Yelensky, G Buchwalter, G Frampton, F Meric-Bernstam, ... Clinical cancer research 20 (7), 1757-1767, 2014 | 482 | 2014 |
| MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation K Lee, JM Giltnane, JM Balko, LJ Schwarz, AL Guerrero-Zotano, ... Cell metabolism 26 (4), 633-647. e7, 2017 | 229 | 2017 |
| Management of chemotherapy extravasation: ESMO–EONS clinical practice guidelines JAP Fidalgo, LG Fabregat, A Cervantes, A Margulies, C Vidall, F Roila European Journal of Oncology Nursing 16 (5), 528-534, 2012 | 213 | 2012 |
| Current questions for the treatment of advanced gastric cancer A Cervantes, D Roda, N Tarazona, S Rosello, JA Perez-Fidalgo Cancer treatment reviews 39 (1), 60-67, 2013 | 197 | 2013 |
| AKT inhibition in solid tumors with AKT1 mutations DM Hyman, LM Smyth, MTA Donoghue, SN Westin, PL Bedard, EJ Dean, ... Journal of Clinical Oncology 35 (20), 2251, 2017 | 189 | 2017 |
| Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients I Chirivella, B Bermejo, A Insa, A Pérez-Fidalgo, A Magro, S Rosello, ... Breast cancer research and treatment 114 (3), 479-484, 2009 | 181 | 2009 |
| Phase 1 Pharmacokinetic/Pharmacodynamic Study of MLN8237-An Investigational, Oral, Selective Aurora A Kinase Inhibitor-In Patients With Advanced Solid Tumors A Cervantes, E Elez, D Roda, JA Ecsedy, T Macarulla, K Venkatakrishnan, ... Clinical Cancer Research, 2012 | 142 | 2012 |
| Concordance of genomic alterations between primary and recurrent breast cancer F Meric-Bernstam, GM Frampton, J Ferrer-Lozano, R Yelensky, ... Molecular cancer therapeutics 13 (5), 1382-1389, 2014 | 103 | 2014 |
| A first-in-human phase I study of the ATP-competitive AKT inhibitor ipatasertib demonstrates robust and safe targeting of AKT in patients with solid tumors C Saura, D Roda, S Roselló, M Oliveira, T Macarulla, JA Pérez-Fidalgo, ... Cancer discovery 7 (1), 102-113, 2017 | 100* | 2017 |
| A phase I open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers U Banerji, EJ Dean, JA Pérez-Fidalgo, G Batist, PL Bedard, B You, ... Clinical Cancer Research 24 (9), 2050-2059, 2018 | 71 | 2018 |
| Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study EM de Dueñas, AL Hernández, ÁG Zotano, RMP Carrión, ... Breast cancer research and treatment 143 (3), 507-515, 2014 | 71 | 2014 |
| Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens JA Pérez-Fidalgo, S Roselló, E García-Garré, E Jordá, P Martín-Martorell, ... Breast cancer research and treatment 120 (1), 245-251, 2010 | 71 | 2010 |
| Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial S Pernas, M Martin, PA Kaufman, M Gil-Martin, PG Pardo, ... The Lancet Oncology 19 (6), 812-824, 2018 | 66 | 2018 |
| Molecular biology of gastric cancer A Cervantes, E Rodriguez Braun, A Perez Fidalgo, I Chirivella González Clinical and Translational Oncology 9 (4), 208-215, 2007 | 66 | 2007 |
| Removal of primary tumor improves survival in metastatic breast cancer. Does timing of surgery influence outcomes? JA Pérez-Fidalgo, P Pimentel, A Caballero, B Bermejo, JA Barrera, ... The Breast 20 (6), 548-554, 2011 | 64 | 2011 |
| MicroRNA profile in very young women with breast cancer M Peña-Chilet, MT Martínez, JA Pérez-Fidalgo, L Peiró-Chova, SS Oltra, ... BMC cancer 14 (1), 1-14, 2014 | 57 | 2014 |
| Pulmonary fibrosis induced by cyclophosphamide A Segura, A Yuste, A Cercos, P López-Tendero, R Gironés, ... Annals of Pharmacotherapy 35 (7-8), 894-897, 2001 | 56 | 2001 |
| Analysis of clinical prognostic factors for survival and time to progression in patients with metastatic colorectal Cancer treated with 5-fluorouracil—based chemotherapy AL Yuste, J Aparicio, A Segura, P López-Tendero, R Gironés, ... Clinical colorectal cancer 2 (4), 231-234, 2003 | 50 | 2003 |
| Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature MT Martínez, JA Pérez-Fidalgo, P Martín-Martorell, JM Cejalvo, V Pons, ... Critical reviews in oncology/hematology 97, 96-106, 2016 | 47 | 2016 |
